Evaluation of the efficacy of a topical formulation containing ASF-1075 in the treatment of chronic hand dermatitis - hand dermatitis

• Conditions: male or female patients with chronic hand dermatitis, aged 18 to 70 years

• Registration Number: EUCTR2005-005793-75-DK
• Lead Sponsor: Astion Danmark A/S

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-01-30
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• men and women aged 18 to 70 years;
• patients suffering from chronic hand dermatitis rated mild to moderate according to Investigator’s global assessment and which has persisted for more than 6 month in spite of attempts to identify and remove cause;
• the physical examination must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study;
• sexually active females of childbearing potential should either be surgically sterile (hysterectomy or tubal ligation), or should use a medically accepted contraceptive regimen: systemic contraceptive (oral, implant, injection), diaphragm or cervical cap with intravaginal spermicide, intrauterine device (IUD), condom with intravaginal spermicide;
• written informed consent obtained.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

• patients with primary hyperkeratotic forms of dermatitis, hand dermatosis other than eczematous dermatoses or with acute infection;
• patients with allergic contact dermatitis if the allergen is identified and they remained in contact with the allergen;
• metalworker;
• Suntan, hyperpigmentation or tattoos in the test fields;
• dark-skinned persons whose skin color prevents ready assessment of skin reactions;
• treatment within 3 months before study day 1 with systemic medications (i.e. glucocorticoids or immune modulators), treatment within two weeks with topical glucocorticosteroids, or treatment with other systemic or locally acting medications which might counter or influence the trial aim within two weeks before study day 1 and during the study;
• UV-therapy within 4 weeks before study day 1 and during the study;
• patients with skin cancer in the medical history;
• patients known to be drug-resistant for this indication;
• evidence of drug or alcohol abuse;
• pregnancy or nursing;
• symptoms of a clinically significant illness that may influence the outcome of the study in the four weeks before study day 1 and during the study;
• participation in another clinical trial involving pharmaceutical products in the four weeks before study day 1;
• known allergic reactions to components of the study preparations;
• in the opinion of the investigator or physician performing the initial examination the patient should not participate in the study, e.g. due to probable noncompliance or inability to understand the study and give adequately informed consent.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified